

6711635

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.

Typed or Printed Name Donna Macedo

Signature

D. Macedo

Date

1/10/03

**INFORMATION
DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(e)**

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

Attorney Docket STAN-201

First Named Inventor CRABTREE, GERALD R. #11/16.T.

Application Number 09/960,708

Confirmation No. 4284

Filing Date September 19, 2001

Group Art Unit 1635

Examiner Name Unassigned

Title: "METHODS AND COMPOSITIONS FOR
MODULATING ANGIOGENESIS"

Sir:

Applicants submit herewith patents and/or publications which may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. § 1.56. While this Statement may be "material" pursuant to 37 C.F.R. § 1.56, it is not intended to constitute an admission that any patent, publication, or other information referred to therein is "prior art" for this invention unless specifically designated as such. A listing of patents and/or publications is shown on enclosed Form PTO-SB/08A and a copy of each patent and/or publication is also enclosed.

Each item of information contained in the Information Disclosure Statement filed herewith was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement (37 C.F.R. 1.97(e)(1)). A copy of the communication is enclosed for the Examiner's convenience.

The Examiner is requested to make the citations listed on the enclosed PTO-SB/08A of record in this application. Applicants would appreciate the Examiner initialing and returning the initialed copy of form PTO-SB/08A, indicating the references have been considered and made of record herein.

No fee is believed due as this statement is being submitted within three months of the mailing date of the enclosed foreign communication. However, if it is determined that fees are required, the Commissioner is hereby authorized to charge any necessary fees associated with this communication or credit any overpayment to Deposit Account No. 50-0815, Order No. STAN-201.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

1/10/03


By:

[Signature]
Bret E. Field, Reg. No. 37,620

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

RECEIVED
JAN 17 2003
TECH CENTER 1600/2900

Please type a plus sign (+) inside this box →



17 / 500000
D.S.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449 (PTO Form 1449) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known	
			RECEIVED JAN 17 2003 TECH CENTER 1600/2900	
Application Number	09/960.708			
Filing Date	September 19, 2001			
First Named Inventor	CRABTREE, GERALD R.			
Group Art Unit	1635			
Examiner Name	Unassigned			
Attorney Docket Number	STAN-201			

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	U.S. Patent Documents		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, columns, lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Documents			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)			

OTHER PRIOR ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		JIANG et al. "Anti-tumor-promoting action of FK506, a potent immunosuppressive agent" <i>Carcinogenesis</i> , Jan. 1993, Vol. 14, pp. 67-71	
		RANGER et al. "The transcription factor NF-Atc is essential for cardiac valve Formation" <i>Nature</i> , March 1998, Vol. 392, pp. 186-190.	
		LUIS ARMESILLA et al. "Vascular endothelial growth factor activated nuclear factor of activated T Cells in human endothelial cells: a role for tissue factor gene expression" <i>Mol. Cell. Biol.</i> March 1999, Vol. 19, No. 3, pp. 2023-2043.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.